Equities Analysts Set Expectations for AQST Q2 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Analysts at HC Wainwright lowered their Q2 2025 EPS estimates for shares of Aquestive Therapeutics in a research note issued on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.22) for the quarter, down from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.82) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.75) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The business had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $12.23 million.

AQST has been the subject of several other research reports. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Lake Street Capital reduced their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $10.67.

Aquestive Therapeutics Stock Down 2.4%

Shares of AQST stock opened at $2.39 on Monday. The company has a market cap of $237.39 million, a price-to-earnings ratio of -5.31 and a beta of 2.02. Aquestive Therapeutics has a 52 week low of $2.12 and a 52 week high of $5.80. The firm has a 50 day moving average of $2.74 and a 200-day moving average of $3.31.

Institutional Trading of Aquestive Therapeutics

Hedge funds have recently bought and sold shares of the business. Summit Wealth & Retirement Planning Inc. acquired a new stake in Aquestive Therapeutics in the 1st quarter valued at $29,000. Victory Capital Management Inc. acquired a new stake in Aquestive Therapeutics in the 1st quarter valued at $31,000. Cambridge Investment Research Advisors Inc. acquired a new stake in Aquestive Therapeutics in the 1st quarter valued at $33,000. New York State Common Retirement Fund grew its position in Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after purchasing an additional 10,700 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Aquestive Therapeutics in the 4th quarter valued at $44,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.